Thursday, March 13, 2025 10:29:06 PM
The New Anavex Patent
Stopping Brain Shrinkage
I just did a quick read-through of the new Anavex patent, TREATMENT AND PREVENTION OF CEREBRAL ATROPHY. A thorough description of the patent would take about 10 pages, with commentaries on each paragraph. But everyone holding or contemplating the taking of an AVXL position should take the time to read through the entire patent application. Even if you are not familiar with the medical terminology, you will discern that this patent is very important.
It shows that Anavex’s sigma-1 receptor agonists are able to actually prevent or stop the shrinkage, atrophy, of various brain tissues, which is associated with or caused by either simple aging or any of the multitude of diseases and pathologies listed in the patent.
Brain atrophy is a major health problem, occurring both from general aging processes and from the many diseases listed in the patent. A diagnosis of a shrinking brain, as definitely revealed by medical imaging, is profoundly ominous. Presently, there is no effective treatment. The brain will continue to wither and lose function, with a lethal outcome.
As in all of the other diseases where blarcamesine has been clinically tested, the use of the drug for prophylaxis or treatment of brain atrophy will be profoundly safe. No disqualifying adverse events (“side effects”).
The drug can be conveniently administered per os, as a swallowed pill.
There is now the firm prospect that the Anavex drug blarcamesine will eventually be approved for sale and as a safe, efficacious therapy for the multitude of diseases and conditions that produce atrophy, shrinkage, of the brain. There is no other drug that can do this as safely, effectively, and inexpensively as can blarcamesine. Once approved, the Anavex drug will become an SOC, a standard of care drug; here for brain atrophy. An effective new medical treatment.
As mentioned in the patent, after the age of forty, human brains begin to slowly shrink, a normal aging process. What, then, do you suppose will be the outcome when middle-aged people get prescribed daily doses of a bit of blarcamesine, to prophylactically slow or delay this normal brain shrinkage? Might it be supposed that people will then live longer, with minimal loss of cognition in their later years?
Once again, the propitious blarcamesine prophylaxis factor.
Stopping Brain Shrinkage
I just did a quick read-through of the new Anavex patent, TREATMENT AND PREVENTION OF CEREBRAL ATROPHY. A thorough description of the patent would take about 10 pages, with commentaries on each paragraph. But everyone holding or contemplating the taking of an AVXL position should take the time to read through the entire patent application. Even if you are not familiar with the medical terminology, you will discern that this patent is very important.
It shows that Anavex’s sigma-1 receptor agonists are able to actually prevent or stop the shrinkage, atrophy, of various brain tissues, which is associated with or caused by either simple aging or any of the multitude of diseases and pathologies listed in the patent.
Brain atrophy is a major health problem, occurring both from general aging processes and from the many diseases listed in the patent. A diagnosis of a shrinking brain, as definitely revealed by medical imaging, is profoundly ominous. Presently, there is no effective treatment. The brain will continue to wither and lose function, with a lethal outcome.
As in all of the other diseases where blarcamesine has been clinically tested, the use of the drug for prophylaxis or treatment of brain atrophy will be profoundly safe. No disqualifying adverse events (“side effects”).
The drug can be conveniently administered per os, as a swallowed pill.
There is now the firm prospect that the Anavex drug blarcamesine will eventually be approved for sale and as a safe, efficacious therapy for the multitude of diseases and conditions that produce atrophy, shrinkage, of the brain. There is no other drug that can do this as safely, effectively, and inexpensively as can blarcamesine. Once approved, the Anavex drug will become an SOC, a standard of care drug; here for brain atrophy. An effective new medical treatment.
As mentioned in the patent, after the age of forty, human brains begin to slowly shrink, a normal aging process. What, then, do you suppose will be the outcome when middle-aged people get prescribed daily doses of a bit of blarcamesine, to prophylactically slow or delay this normal brain shrinkage? Might it be supposed that people will then live longer, with minimal loss of cognition in their later years?
Once again, the propitious blarcamesine prophylaxis factor.
Recent AVXL News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
